Tempus AI completed the acquisition of Ambry Genetics from Konica Minolta for $600m.

Tempus AI, an American health technology company, completed the acquisition of Ambry Genetics, a provider of hereditary cancer screening, from Konica Minolta, a Japanese multinational technology company, for $600m. “This acquisition complements our strategy of leveraging diagnostics and data to drive innovation, further strengthening our ability to deliver cutting-edge solutions to clinicians, patients, and life sciences companies. We are excited to welcome Ambry to the Tempus team as we work together to improve patient outcomes and transform treatment journeys through the power of technology,” Eric Lefkofsky, Tempus Founder and CEO.